Adding pulse oximetry shows no benefit in COVID-19
Apr 13, 2022
No improvement was observed in patients using pulse oximetry added to standard monitoring.
AHCA / NCAL, AMDA blast ‘short-sighted’ plans to discharge people with COVID-19 from hospitals to...
By
Lois A. Bowers
Mar 30, 2020
“The question all state officials must consider is whether the risk of introducing a virus with an estimated 30% or higher mortality rate into a nursing home or assisted living community outweighs...
Mortality risk increased for six months after COVID-19 in veterans
Aug 31, 2023
Those who survived COVID-19 had reduced mortality on days 181 to 365 and 366 to 730.
Sleep disturbance common after COVID-19 hospitalization
Apr 17, 2023
Associations were seen for overall sleep quality, deterioration in sleep quality after admission and sleep regularity with higher dyspnea scores.
Plasma viral antigen linked to baseline severity of COVID-19
Sep 07, 2022
High levels of plasma viral antigen are linked to outcomes such as worse pulmonary status and longer time to hospital discharge.
Metformin, ivermectin, fluvoxamine do not prevent severe COVID-19
Aug 19, 2022
No difference in the primary end point was seen with any of the three medications versus placebo among adults with overweight or obesity.
Seroprevalence to SARS-CoV-2 has increased over time
Nov 17, 2022
The global seroprevalence from infection or vaccination reached 59.2% by September 2021.
Early effectiveness assessed for fourth dose of BNT162b2 vaccine
Apr 21, 2022
The difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization and severe COVID-19.
Surges in hospital caseload tied to higher COVID-19 mortality
Jul 09, 2021
Patients receiving care in hospitals during surges have up to twice the COVID-19 mortality risk versus those seen in nonsurging hospital-months.
Two-dose Novavax vaccine protects against SARS-CoV-2 infection
Jul 06, 2021
Vaccine efficacy in adults was 89.7% overall, 86.3% against B.1.1.7 (alpha) variant, and 96.4% against non-B.1.1.7 variants